Sirukumab - Janssen Biotech

Drug Profile

Sirukumab - Janssen Biotech

Alternative Names: CNTO-136; PLIVENSIA™; Shirukumabu

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor
  • Developer Centocor; GlaxoSmithKline; Janssen Biotech
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Giant cell arteritis
  • Phase II Asthma; Lupus nephritis; Major depressive disorder
  • Preclinical Atherosclerosis
  • Preregistration Submission Withdrawal Rheumatoid arthritis

Most Recent Events

  • 20 Nov 2017 GlaxoSmithKline had withdrawn a phase III trial in Polymyalgia rheumatica prior to enrolment (NCT02899026)
  • 17 Oct 2017 Discontinued - Phase-III for Rheumatoid arthritis in Moldova, Puerto Rico, India, Brazil, Argentina, New Zealand, Mexico, Australia, Taiwan, Ukraine, South Africa, Russia, Serbia, Malaysia, South Korea, Colombia, Chile, Canada (SC)
  • 17 Oct 2017 Regulatory submission withdrawn for Rheumatoid arthritis (Combination therapy) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top